A hepatitis A, B, C and HIV prevalence and risk factor study in ever injecting and non-injecting drug users in Luxembourg associated with HAV and HBV immunisations

Table 2 Seroprevalence (%)

		OTC N/Ntotal	ITC N/Ntotal	PC N/Ntotal	IDUs N/Ntotal	nIDUs % N/Ntotal
	Active HBV (HBs ag+)	1.5 2/130	0 0/54	7.0 8/115	3.9 10/254	0 0/45
HBV (cured or active infection)	Cured HBV (HBs ab+, HBc ab+)	13.1 17/130	14.8 8/54	23.5 27/115	19.3 49/254	6.7 3/45
	Total HBVab *	22.3 29/130	16.7 9/54	34.8 40/115	29.1 74/254	8.9 4/45
HBV vaccination (HBs ab+)		39.2 51/130	57.4 31/54	45.2 52/115	46.1 117/254	37.8 17/45
HBV seropositivity (all types)		61.5 80/130	74.1 40/54	80.0 92/115	75.2 191/254	46.7 21/45
HCV (Elisa +, RIBA +) HCVab		57.3 75/131	75.4 46/61	86.3 107/124	81.3 218/268	19.1 9/47
HAV (IgG+) HAVab		54.7 70/128	57.1 24/42	68.3 41/60	57.1 108/189	65.9 27/41
HIV-1 HIVab		1.5 2/130	0 0/49	7.7 5/65	2.5 5/202	4.8 2/42

ISSN: 1471-2458